Countering emerging Sars-CoV-2 variants
Recorded event – May 5, 2021
The global COVID-19 pandemic created an urgent need for protective interventions.
However, SARS-CoV-2 continues to evolve, and new viral variants harboring mutations appear to enable escape from antibody neutralization. Multiple approaches will likely be required to combat these threats as the scientific and pharmaceutical communities continue to develop anti-SARS-CoV-2 therapeutics and vaccines.
Dr. Jesse Erasmus, PhD from the University of Washington School of Medicine discusses his approach to addressing these emergent challenges. In the webinar, you will learn how Dr. Erasmus mitigated key design and discovery hurdles to design a framework for the scalable manufacturing and improved stability required for global vaccine distribution.
Dr. Erasmus further discusses his development of a two-vialed replicating RNA (repRNA) vaccine and lipid inorganic nanoparticle (LION) platform that can be mixed immediately prior to injection.
Jesse Erasmus is acting assistant professor at the University of Washington School of Medicine and the director of virology at HDT Bio. His research focuses on studying virus-derived mechanisms of gene expression for the development of new RNA vaccine and therapeutic technologies.
By clicking submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.